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Abstract
Purpose To estimate the incidence of herpes zoster (HZ)
and rates of post-zoster pain in both the total study popu-
lation and separately in patients with selected conditions/
treatments associated with altered immune function.
Methods The health administrative claims databases for
commercially insured, Medicare, and Medicaid popula-
tions, together accounting for approximately 51 million
insured individuals, were analyzed between 2005 and 2009
in a retrospective cohort study. Incidence of HZ episodes
per 1,000 person-years (PY) was estimated in all study
populations as well as within nine potentially immune-
altering conditions. Among patients with HZ, the 6-month
rate of persistent post-zoster pain was estimated.
Results Analysis of 90.2 million PY at risk revealed that
the incidence of HZ in the total study population was 4.82/
1,000 PY. The incidence of HZ was highest among patients
with bone marrow or stem cell transplant (43.03 %) fol-
lowed by solid organ transplant, human immunodeficiency
virus infection, and systemic lupus erythematosus [95 %
confidence interval (CI) 15.19–17.41 %]. HZ incidence
rates were higher among persons on immunosuppressants/
chemotherapy than among non-users. In the total study
population, HZ incidence increased with age (18–49 years:
3.37/1,000 PY; 65? years: 8.43/1,000 PY; P \ 0.01) and
female gender (incidence ratio vs. male 1.39, 95 % CI
1.38–1.40 %). The 6-month rate of persistent post-zoster
pain was 4.29 % (95 % CI 4.22–4.36 %), which was higher
in patients with the selected conditions.
Conclusions Despite providing a relatively small fraction
of overall HZ cases, persons with immune function-altering
conditions make a large contribution to the societal
healthcare burden because they have a higher risk of
developing HZ and persistent post-zoster pain. These risk
factors should be considered in HZ prevention efforts.
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Introduction
Herpes zoster (HZ) is caused by the reactivation in sensory
ganglia of latent varicella-zoster virus (VZV), with clinical
manifestations of an acute, painful dermatomal vesicular
rash that can be followed by persistent post-zoster pain
(postherpetic neuralgia) in the same dermatome [1]. HZ
results in a significant economic burden in direct healthcare
costs [2] and loss of productivity [3, 4]. The occurrence of
post-zoster debilitating pain leads to higher direct health-
care costs [5] and adversely impacts the quality of life
[6, 7].
Population studies in the USA in the early 1990s esti-
mated the incidence of HZ to be 2.2/1,000 person-years
(PY). [8]. In comparison, recent estimates of HZ incidence
in the USA were 3–4/1,000 PY based on data up to 2005
[9–11]. Another USA study reported a trend toward
increasing HZ incidence from 1.7/1,000 PY in 1993 to 4.4/
1,000 PY in 2006 [12]. A similar observation was found in
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a recent study on the Medicare elderly population between
1991 (9.9/1,000 PY) and 2009 (13.8/1,000 PY) [13].
The onset of HZ is believed to result from declining
VZV-specific cell-mediated immunity (CMI) [14], result-
ing in patients with conditions or treatments that alter
immune function being more susceptible to HZ. The inci-
dence of HZ has been examined in patients with various
conditions or treatment scenarios that alter CMI, including
solid organ transplant (SOT) [15–17], cancer [18, 19],
human immunodeficiency virus (HIV) infection [20, 21],
and autoimmune diseases, such as systemic lupus erythe-
matosus (SLE) [18, 22, 23], rheumatoid arthritis (RA) [18,
24–26], and inflammatory bowel disease (IBD) [18, 27], or
together as a group [9]. Although the risk of HZ has been
evaluated in patients with individual conditions, a study
that includes a large sample size from the general popu-
lation enabling the assessment of the comparative risk of
HZ among those conditions will be informative.
There is currently a licensed vaccine to help prevent HZ,
as well oral medication that must be taken soon after its
onset. Therefore, defining the risk of different populations
could be helpful in implementing strategies to decrease the
burden of HZ. The objective of this study was to estimate
the incidence of HZ both in the total study population and
separately in patients with selected conditions/treatments
associated with altered CMI. Among patients with HZ, the
rate of persistent post-zoster pain was also evaluated.
Methods
Data sources
The analysis was based on data extracted from three
administrative medical and pharmacy claims databases on
three large populations, namely, (1) commercially insured
working adults and their dependents (approx. 30 million)
from over 100 large self-insured employers and health
plans; (2) Medicare-eligible retirees with Medicare sup-
plemental insurance (approx. 3 million); (3) Medicaid
beneficiaries from 12 states (approx. 22 million). The
databases contained information on enrollment status, type
of healthcare plan, and demographic characteristics, such
as age, gender, and region of residence. The following
information was captured on pharmacy claims: National
Drug Code, dispensing date, quantity, days supplied, and
plan- and patient-paid amounts. Details of healthcare ser-
vice encounters were recorded on the medical claims,
including date and place of service, provider type, plan-
and patient-paid amounts, and the international classifica-
tion of diseases, ninth revision, clinical modification (ICD-
9-CM) diagnosis and procedure codes across all settings.
Study populations
For inclusion in the study we first selected adults captured
the databases aged C18 years between 01 January 2005
and 31 December 2009. We excluded individuals from the
Medicare population aged \65 years and Medicaid enrol-
lees aged C65 years, enrollees with dual eligibility of
Medicaid and Medicare, and Medicaid enrollees lacking
drug coverage because their medical and pharmacy claims
were not completely captured in the database. To estimate
the incidence of new episodes of HZ, we considered indi-
viduals with continuous medical and pharmacy benefits for
a period of at least 6 months without any diagnosis of HZ
(ICD-9-CM 053.xx). We also determined separately the
incidence of HZ among patients with the following nine
potentially CMI-altering conditions: cancer (excluding skin
cancer), HIV infection, bone marrow or stem cell trans-
plantation (BMSCT), SOT, SLE, RA, IBD, psoriasis, and
multiple sclerosis (MS). These conditions were identified
by ICD-9-CM diagnosis codes and procedures of the
medical claims (Appendix Table 5). For cancer, we
required at least two medical claims on two separate dates
to ascertain a diagnosis. A patient could have multiple
conditions and could also contribute to multiple disease
populations. The follow-up for the total study population
began after the subject had been diagnosed HZ free for
6 months (index date); the follow-up for the selected dis-
ease populations began after the subject had been diag-
nosed HZ free for at least 6 months and after the first
disease-related claim.
Ascertaining incident HZ cases
Herpes zoster episodes were ascertained based on principal
or secondary diagnosis codes of 053.0–053.11, 053.14,
053.19, 053.2x–053.9x. we excluded two post-herpetic
neuralgia-related diagnoses (053.12, 053.13) to prevent
mis-classification of prevalent HZ cases.
Identification of persistent post-zoster pain
Patients with HZ who had at least 6 months continuous
enrollment following the incident HZ diagnosis were
assessed for persistent post-zoster pain, which was defined
in this study as: (1) a diagnosis of post-herpetic trigeminal
neuralgia (ICD-9-CM 053.12) or post-herpetic polyneu-
ropathy (ICD-9-CM 053.13), (2) a diagnosis of HZ with
other nervous system complications (ICD-9-CM 053.19)
and more than 30-day supply of medications commonly
used for post-zoster pain (Appendix Table 6 ), or (3)
unspecified neuralgia, neuritis, or radiculitis (ICD-9-CM
729.2) if it first appeared after the HZ diagnosis.
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Patient characteristics
Age and gender were assessed at the index date. Chemo-
therapy treatments among patients with cancer and the
administration of immunosuppressants for the selected
conditions, except for HIV-infected individuals, were
recorded from pharmacy claims and procedure codes in
medical claims during the study period (Appendix Table 7).
Statistical analysis
To calculate the incidence of HZ, enrollees were followed
from the index date to the end of their continuous enroll-
ment or the date of the incident HZ episode, whichever
came first. The incidence of HZ was estimated as the
number of incident HZ cases divided by the person-time at
risk and presented as number of cases/1,000 PY. The 95 %
confidence interval (CI) of incidence was estimated
assuming a Poisson distribution.
Incidence of HZ was reported by age (age categories:
18–49, 50–59, 60–64, 65? years) and by gender. Since
not all selected conditions are immunocompromising
when untreated, we also estimated the incidence of HZ by
use of immunosuppressants/chemotherapies. The incident
rate ratio (IRR) of HZ between these mutually exclusive
subgroups was reported, and the 95 % CI of IRR was
estimated based on the Mantel–Haenszel combined esti-
mate. The Mantel extension of the Armitage–Cochran
trend test was used to assess the linear trend in incidence
rate from age group 18–49 to 65? years. Among patients
with HZ who had at least 6 months of follow-up, we
estimated the 6-month rates of persistent post-zoster pain.
Analyses were conducted using SAS ver. 9.2 (SAS Insti-
tute, Cary, NC).
Results
Characteristics of study sample
There were 218,025,906 enrollees available in the Com-
mercial, Medicare and Medicaid MarketScan database
from 2005 to 2009. Among these, 51,022,838 enrollees met
the inclusion/exclusion criteria. The mean age of the total
study population was 43 years, 54.0 % were female, and
the average follow-up was 1.8 years (Table 1). The mean
age of the selected conditions was the lowest for patients
with HIV infection (mean age 42 years) and the highest for
patients with cancer (mean age 60 years). Use of immu-
nosuppressants was most common among patients with
SOT (67.4 %) or BMSCT (58.6 %), followed by RA
(49.4 %), SLE (47.0 %), IBD (37.8 %), MS (33.0 %), and
psoriasis (30.3 %). Of the cancer patients, 28.7 % had
pharmacy claims for chemotherapies.
Incidence rate of HZ
In the total study population, 435,378 new cases of HZ
occurred during 90,236,779 PY (Table 2), indicating an
incidence of 4.82/1,000 PY (95 % CI 4.81–4.84). The
incidence of HZ among the selected conditions was higher
than that in the total study population (Table 2). The
incidence of HZ was highest among patients with BMSCT
(43.03/1,000 PY; 95 % CI 39.96–46.28; ninefold higher
Table 1 Characteristics of the study sample




Age (years) Age group (%) Sex Use of
immunosuppressants/









Total study population 51,022,838 43.1 15.8 66.0 19.2 6.2 8.6 46.0 54.0 N/A
Bone marrow or stem cell
transplant
14,679 49.3 12.8 42.8 35.3 15.5 6.5 52.4 47.6 58.6
Solid organ transplant 61,189 49.7 12.5 44.5 34.0 13.1 8.4 59.2 40.8 67.4
Human immunodeficiency
virus infection
121,956 41.8 10.6 76.8 18.8 3.2 1.2 69.8 30.2 N/A
Systemic lupus
erythematosus
144,137 46.9 13.2 56.7 27.5 8.7 7.1 12.2 87.8 47.0
Rheumatoid arthritis 571,555 52.7 13.9 39.4 31.8 12.7 16.1 26.7 73.3 49.4
Cancer 1,462,356 59.5 13.8 21.8 30.1 16.6 31.5 45.1 54.9 28.7
Inflammatory bowel disease 345,565 47.0 15.0 55.5 25.1 9.2 10.2 43.5 56.5 37.8
Multiple sclerosis 146,261 46.3 12.1 60.1 27.5 7.2 5.2 24.1 75.9 33.0
Psoriasis 536,770 46.2 14.7 57.2 24.8 9.1 8.9 45.6 54.4 30.3
SD, Standard deviation; N/A, not available
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than that of the total study population). Patients with SOT
(17.04/1,000 PY; 95 % CI 16.23–17.88), HIV (17.41/1,000
PY; 95 % CI 16.81–18.01) and SLE (15.19/1,000 PY;
95 % CI 14.69–15.69) had HZ incidence rates over three-
fold higher than that in the total study population. The
incidence of HZ in the remaining evaluated conditions was
between two- and threefold higher than that of the total
study population, including RA (12.24/1,000 PY; 95 % CI
12.02–12.47), cancer (11.70/1,000 PY; 95 % CI
11.57–11.83), IBD (9.31/1,000 PY; 95 % CI 9.06–9.56),
MS (8.60/1,000 PY; 95 % CI 8.24–8.96) and psoriasis
(8.03/1,000 PY; 95 % CI 7.84–8.22).
Incidence rate ratio of HZ for patients receiving
immunosuppressants or chemotherapy
Across the selected conditions, the incidence rates of HZ
were higher among users of immunosuppressants or che-
motherapy than among non-users (Table 2). Figure 1
illustrates the IRR with 95 % CI of users versus non-users.
Irrespective of the underlying conditions, users of immu-
nosuppressant or chemotherapy had an approximately
50 % higher risk of HZ than those without these inter-
ventions. The increased risk of HZ associated with im-
munosuppressants or chemotherapy was highest among
patients with BMSCT (IRR 1.70, 95 % CI 1.45–2.01) and
lowest among patients with SLE (IRR 1.46, 95 % CI
1.36–1.56).
Incidence rate and rate ratio of HZ by age and gender
As shown in Table 3, the incidence rate of HZ in the
total study population increased significantly with age
(P \ 0.01) from 3.37/1,000 PY (95 % CI 3.35–3.38) for
those aged 18–49 years to 8.43/1,000 PY for those aged
65? years (95 % CI 8.37–8.49). Compared to individ-
uals aged 18–49 years, the HZ incidence rate was 91 %
higher (IRR 1.91, 95 % CI 1.90–1.92) among those
aged 50–59 years, 129 % higher (IRR 2.29, 95 % CI
2.27–2.31) among those aged 60–64 years and 150 %
higher among those aged 65? years (IRR 2.50, 95 %
CI 2.48–2.52). An increasing HZ incidence with age
was also observed among patients with SOT, SLE, RA,
cancer, IBD, MS, and psoriasis (all P \ 0.01). How-
ever, except for persons with psoriasis, the risk of HZ
in these conditions was less influenced by age (as
suggested by the IRRs toward the null) than in the total
study population. Among patients with BMSCT, there
was no significant increase in HZ incidence with age
(Table 3). A decreasing trend of incidence rate was
observed among patients with HIV (P \ 0.01), from
17.8 to 16.0/1,000 PY among those aged \65 years to
10.70/1,000 PY (95 % CI 6.62–16.35) in those aged
65? years.
In the total study population (Fig. 2), the incidence
rate of HZ among females was 39 % higher than that of
males (IRR 1.39, 95 % CI 1.38–1.40). Among patients











Incidence by use of immunosuppressants or
chemotherapy
Users Non-users
Incidencea 95 % CI Incidencea 95 % CI
Total study population 435,378 90,236,779 4.82 4.81–4.84 N/A – N/A –
Bone marrow or stem
cell transplant
726 16,870 43.03 39.96–46.28 51.50 (47.18–56.11) 30.23 26.21–34.68




3,207 184,198 17.41 16.81–18.01 N/A – N/A –
Systemic lupus
erythematosus
3,540 233,096 15.19 14.69–15.69 17.85 (17.11–18.61) 12.23 11.58–12.90
Rheumatoid arthritis 11,446 934,811 12.24 12.02–12.47 14.28 (13.96–14.61) 9.64 9.34–9.94
Cancer 29,698 2,538,706 11.70 11.57–11.83 15.63 (15.33–15.93) 10.25 10.11–10.40
Inflammatory bowel
disease
5,257 564,563 9.31 9.06–9.56 12.07 (11.64–12.51) 7.15 6.86–7.45
Multiple sclerosis 2,146 249,551 8.60 8.24–8.96 11.00 (10.35–11.68) 7.05 6.64–7.49
Psoriasis 6,927 862,544 8.03 7.84–8.22 10.85 (10.49–11.23) 6.47 6.26–6.68
HZ, Herpes zoster; CI, confidence interval
a Incidence presented as number of cases per 1,000 person-years (PY)
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BMSCT: bone marrow or stem cell transplant; SOT: solid organ transplant; SLE: systemic lupus erythematosus; RA: rheumatoid



















Fig. 1 Incidence rate ratio of
herpes zoster (HZ) for users of
immunosuppressants or
chemotherapy (users vs. non-
users). BMSCT Bone marrow or
stem cell transplant, SOT solid
organ transplant, SLE systemic
lupus erythematosus, RA
rheumatoid arthritis, IBD
inflammatory bowel disease, MS
multiple sclerosis
Table 3 Incidence and rate ratio of herpes zoster by age group
Characteristics of the
study population
Incidencea, b (95 % CI) Incidence rate ratio (95 % CI)












40.20 (35.6–45.12) 43.22 (38.2–48.65) 50.71 (41.8–60.92) 44.73 (33.2–58.97) 1.08 (0.91–1.27) 1.26 (1.01–1.57) 1.11 (0.81–1.51)
Solid organ
transplant




17.83 (17.1–18.55) 16.42 (15.1–17.75) 16.02 (12.8–19.78) 10.70 (6.62–16.35) 0.92 (0.84–1.01) 0.90 (0.72–1.11) 0.60 (0.37–0.92)
Systemic lupus
erythematosus
13.39 (12.7–14.04) 15.40 (14.5–16.35) 20.01 (18.0–22.18) 23.39 (21.0–25.91) 1.15 (1.07–1.24) 1.49 (1.33–1.67) 1.75 (1.56–1.96)
Rheumatoid arthritis 8.32 (8.02–8.63) 12.75 (12.3–13.15) 15.31 (14.5–16.08) 18.34 (17.6–19.04) 1.53 (1.46–1.61) 1.84 (1.73–1.96) 2.20 (2.09–2.32)
Cancer 8.39 (8.15–8.64) 10.94 (10.7–11.17) 13.05 (12.6–13.42) 14.14 (13.8–14.40) 1.30 (1.26–1.35) 1.55 (1.49–1.62) 1.68 (1.63–1.74)
Inflammatory bowel
disease
6.89 (6.59–7.19) 11.02 (10.5–11.55) 11.67 (10.7–12.69) 15.48 (14.4–16.53) 1.60 (1.50–1.71) 1.69 (1.54–1.86) 2.25 (2.08–2.43)
Multiple sclerosis 6.83 (6.42–7.27) 10.75 (10.0–11.52) 11.91 (10.2–13.75) 12.35 (10.4–14.50) 1.57 (1.43–1.73) 1.74 (1.48–2.04) 1.81 (1.51–2.15)
Psoriasis 5.28 (5.08–5.49) 9.46 (9.08–9.86) 13.11 (12.2–13.99) 15.39 (14.5–16.27) 1.79 (1.69–1.90) 2.48 (2.30–2.68) 2.91 (2.72–3.12)
a Incidence rate presented as number of cases per 1,000 PY
b Linear trend of incidence rate was significant at P \ 0.01 except for bone marrow or stem cell transplant (P = 0.08)
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with BMSCT, the HZ incidence rate was not signifi-
cantly different between females and males (IRR 0.92,
95 % CI 0.79–1.07), but the incidence rate of
HZ among females was higher than males in the
other conditions, with IRRs ranging from 1.10 (95 %
CI 1.02–1.19) in HIV to 1.36 (95 % CI 1.30–1.42) in
RA.
Six-month rate of persistent post-zoster pain
There were 322,877 patients who had [6 months of con-
tinuous enrollment after the onset of HZ to provide an
estimate of the 6-month rates of persistent post-zoster pain
(Table 4). Overall, the 6-month rate was 4.29 % (95 % CI
4.22–4.36). In general, the rate was higher among patients
with the selected conditions than among the total study
population, with BMSCT being the highest (10.18 %, 95 %
CI 7.83–13.14). For the other selected immunocompro-
mised conditions, the rate of persistent post-zoster pain
ranged from 5.08 % among patients with psoriasis (95 %
CI 4.51–5.73) to 7.22 % among patients with RA (95 % CI
6.68–7.80).
BMSCT: bone marrow or stem cell transplant; SOT: solid organ transplant; HIV: Human immunodeficiency virus infection; 
























Fig. 2 Incidence rate ratio of































Rheumatoid arthritis 8,294 7.22 6.68–7.80




Multiple sclerosis 1,563 5.57 4.53–6.82
Psoriasis 4,978 5.08 4.51–5.73
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Discussion
The objectives of this study were to estimate the incidence
of HZ and the rate of persistent post-zoster pain within
6 months after the incident HZ event among adults in the
total study population and in those with selected potentially
CMI-altering conditions. The relative impact of age, gen-
der and exposure to immunosuppressants or chemothera-
pies on the incidence of HZ were also assessed. Using a
large nation-wide, multiple-payer U.S. administrative
claims database, we found a HZ incidence of 4.82/1,000
PY for the total study population. A higher incidence was
observed associated with female gender and older age. The
incidence of HZ was highest among patients with BMSCT,
followed by SOT, HIV, and SLE (43.03–15.19/1,000 PY).
The other conditions (RA, cancer, IBD, MS, and psoriasis)
had an incident two- to threefold that of the total study
population (12.24–8.03/1,000 PY).
As both the incidence of HZ and the prevalence of risk
factors change over time, it is important to assess the most
current disease burden. Therefore, this study, derived from
51 million people participating in three different healthcare
insurance programs between 2005 and 2009, provides
recent data on the epidemiology of HZ in the USA.
Although our study population might not be directly
comparable to those of previous studies due to differences
in data sources and patient profiles (e.g., age and gender),
the higher incidence of HZ (4.82/1,000 PY) observed in
our study is consistent with an increasing trend of HZ
incidence over time [8–13].
Within the nine selected conditions, the risk of HZ was
two- to tenfold greater than that seen in the total study
population. Although it is difficult to compare absolute
values from past studies given the differences in method-
ology, populations, and time period, our findings are con-
sistent those of earlier studies in that there is a strong effect
of immune suppression on the risk of HZ [9, 18, 19, 23, 25,
27]. In our study, a more accurate comparison across
conditions was possible because patients with these selec-
ted conditions were drawn from one large population using
the same methodology. Although the majority of HZ cases
occurred among individuals without concurrent alteration
in immune function [9, 11], the higher risk of HZ among
patients with altered immune function may be more bur-
densome from an economic perspective. For example, the
higher rate of persistent post-zoster pain observed in these
patients will likely require significant healthcare resources
and would decrease their productivity and/or quality of life.
The comparative risk estimates observed will be informa-
tive for the clinicians and payers in targeting populations at
a higher risk.
This study also evaluated the comparative effect of
various factors across these high-risk conditions.
Consistent with the literature [8–12, 28], our study found a
higher risk of HZ associated with older age in the total
study population. Among the selected conditions there was
an increasing age trend for HZ except for BMSCT and HIV
infection. However, it is worth noting that the absolute risk
ratio of HZ associated with older age in subjects with these
conditions is much smaller relative to that in the total study
population. This could be because the increased risk
associated with older age (mediated by declining VZV-
specific CMI) is relatively small compared with that
associated with strong immune suppressive effects (on
VZV-specific CMI) of the selected diseases and their
therapies. The unexpected decreasing risk of HZ associated
with older age in HIV-infected people in our study appears
to be driven by the lower risk among patients aged
C65 years (IRR = 0.60 compared to patients aged
18–49 years; 95 % CI 0.37–0.92). A possible explanation
is that older patients who do survive with HIV might be
relatively more immune competent and more likely to
adhere to treatment than younger patients.
As has been observed in many earlier studies [9, 11, 12,
29–37]—but not all [8, 18, 24, 38, 39]—we found a higher
risk of HZ associated with female gender. No biological
explanation has been proposed for this finding. Since we
used an administration health claims data, the behavioral
differential in health-seeking behavior could not be ruled
out. Interestingly, no gender effect in patients with BMSCT
was found among our study population, which supports our
hypothesis regarding the declining role of other risk factors
when a strong immune suppressive effect is present. Our
study also confirmed the higher risk associated with im-
munosuppressants and chemotherapies previously reported
[19, 22, 24, 26, 37].
Post-herpetic neuralgia is the most common complica-
tion of HZ. The authors of two studies reported that
18–27 % of the adult patients with HZ in their studies had
persistent pain beyond 90 days [11, 40]. This is substan-
tially lower (4.29 % for persistent post-zoster pain) than
that in our study. However, the rate of post-zoster pain in
this article is not equivalent to that of the more usually
reported post-herpetic neuralgia, as we used an algorithm
combining diagnostic codes and the utilization of pain-
related medications to identify patients likely to have
experienced persistent post-zoster pain. Thus, it remains
challenging to accurately identify patients experiencing
persistent post-zoster pain using the ICD-9-CM diagnosis
system, which does not have a specific post-herpetic neu-
ralgia/diagnosis code. Assuming that the disease-specific
effects on this algorithm are random (i.e., had the same
ability to discriminate this condition between the sub-
groups even if there was any mis-classification), the rela-
tive rates between populations is informative. Our findings
of a higher rate of persistent post-zoster pain in the
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evaluated conditions relative to the total study population
indicate that persistent post-zoster pain occurs even when
the inflammatory response is blunted.
This study has several structural limitations. Diagnoses
were derived from administrative billing records which are
subject to mis-coding or under-coding and which are not
validated against medical charts. Moreover, we only captured
health encounters that were reimbursed by the plan. Hence,
our data source did not capture the individuals developing
HZ/persistent post-zoster pain who did not seek healthcare.
Healthcare services or prescription medications paid com-
pletely out-of-pocket or by other supplemental insurance
were not observed, as were any medicines that had been
administered on experimental protocols. Exposure to im-
munosuppressants, chemotherapies, and pain-related medi-
cations could be mis-classified if they were not reimbursed by
the health plan or patients did not actually receive the treat-
ment. For example, the use of immunosuppressants appeared
to be lower than anticipated in SOT patients; such mis-clas-
sification could lead to biased estimates in either direction.
The estimated incidence within the conditions with altered
immune function were also subject to detection bias, since
these patients had more frequent healthcare encounters,
which would bias the comparative results between the total
study population and the immune-suppressed patients.
Finally, our findings might not be generalizable to other
populations such as un-insured or veterans.
Conclusions
In this study we combined three large databases to assess
the current epidemiology of HZ. Despite providing a frac-
tion of overall HZ cases, persons with immune function-
altering conditions have a higher risk of developing HZ and
persistent post-zoster pain. Older age and female gender
were also associated with higher risks. These risk factors
should be considered in the design of preventive programs
that include the use of safe and effective HZ vaccines.
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Appendix
Tables 5, 6 and 7.
Table 5 International classification of diseases, ninth revision, clin-


















































Multiple sclerosis 340.x Multiple sclerosis
Psoriasis 696.x Psoriasis and similar
disorders
ICD-9-CM, International classification of diseases, ninth revision,
clinical modification
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